Pasar al contenido principal

NUEVAS FUNCIONES DE TRAF1 EN LA RESPUESTA INMUNE, EN LA HOMEOSTASIS Y EN EL ENVEJECIMIENTO DE LOS LINFOCITOS T

PID2022-136909OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Editorial: Community series in mouse models of B cell malignancies, volume II

  • Pérez-Chacón, Gema
  • Vincent-Fabert, Christelle
  • Zapata, Juan M.
B-cell malignancies are a diverse group of cancers that originate from B lymphocytes at different developmental and differentiation stages exhibiting distinctive progression patterns and symptoms. Prognosis depends on the histological type, disease stage, and available treatment (reviewed in (1–3). In the last decades, advances in medical research have significantly improved the outcomes for these patients. However, a deeper knowledge on the origin, progression, and development of refractoriness and relapse is needed for providing patients with new treatments with better remission rates or longer progression-free survival. In addition, tools allowing a more accurate preclinical prediction on how new therapeutic approaches would work in clinics are also needed., GP-C and JMZ were supported by a grant from the Agencia Estatal de Investigacion (PID2022-136909OB-I00). CV-F was supported by the International Waldenström Macroglobulinemia Fundation, the “Fondation ARC pour la recherche sur la cancer” and the “Ligue contre le cancer comités Haute-Vienne et Creuse”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Indole-3-carbinol is an inhibitor of KV1.3 potassium voltage-gated channel activity in chronic lymphocytic leukemia cells

  • Baena-Nuevo, M.
  • Vera-Zambrano, Alba
  • Martínez-Laperche, Carolina
  • Buño, Ismael
  • Muñoz-Calleja, Cecilia
  • Valenzuela, Carmen
  • Zapata, Juan M.
  • Pérez-Chacón, Gema
Potassium voltage-gated channels are attractive drug targets for cancer treatment. In this report, we show that KV1.3 current amplitude is greater in CLL cells from refractory patients compared to CLL cells from untreated patients, further supporting a role for Kv1.3 channel as a target for refractory CLL disease. Indole-3 carbinol (I3C) is a clinically tested natural product found in edible Brassica plants. Here we show that I3C inhibits KV1.3 currents in transfected HEK293 (43.9 ± 7.6 %; 50 μM I3C), Burkitt's lymphoma BL60.2 (52.2 ± 5.2 %; 10 μM) and chronic lymphocytic leukemia (CLL) (57.7 % ± 5.2; 10 μM) cells. I3C inhibition was concentration-dependent in HEK293 (IC50 = 54 μM; nH = 3.2), BL60.2 (IC50 = 1.06 μM; nH = 0.53) and CLL (IC50 = 5.2 μM; nH = 0.95) cells, and the effect on KV1.3 was produced in a voltage-, time- and use-dependent manner, consistent with an open state blockade mechanism. I3C also inhibited KV11.1 currents, but failed to inhibit other KV channels and Kca3.1. Interestingly I3C did not induce mitochondrial depolarization of CLL cells, suggesting that I3C only targets plasma, but not mitochondria, Kv1.3 channels. I3C and derivatives 6-methyl-I3C and 3,3′-diindolylmethane, but no other indoles, that we previously showed induced apoptosis in Burkitt's and CLL cells, also efficiently inhibited KV1.3 currents. However, I3C-mediated KV1.3 currents inhibition was observed in CLL cells irrespective of their sensitivity to I3C-induced cell death, thus indicating that plasma membrane KV1.3 inhibition is not sufficient to induce CLL cell death., This study was supported by projects PID2019-110405RB-I00 and PID2022-136909OB-I00 (to JMZ), PID2019-104366RB-C21 and PID2022-137214OB-C21 (to CV), all funded by MCIN/AEI/10.13039/501100011033 and ERDF, EU. This study was also supported by Grant CB/11/00222 funded by Instituto de Salud Carlos III CIBERCV (to CV) and by 2023AEP049 funded by CSIC (to CV). It was also supported by S2022/BMD-7223 (to CV) and P2022/BMD-7225 (to JMZ) funded by Consortium in Biomedicine of Comunidad de Madrid., Peer reviewed